What Is CBN? What Research Says About Cannabinol

CBD and Delta 9 THC may be the best-known cannabis compounds, but they are only part of a much larger group of cannabinoids found in Cannabis sativa. One of the lesser-known members of that group is cannabinol, or CBN.

CBN has developed a particularly strong association with nighttime cannabinoid products, and it is frequently marketed as the "sleep cannabinoid." But the science behind that reputation is more complicated than the marketing suggests.

Human research on CBN has expanded considerably in recent years. Randomized controlled trials have now examined CBN and sleep, researchers continue to study how CBN interacts with cannabinoid receptors, and laboratory and animal studies are exploring several other areas of CBN biology.

The important distinction is between what researchers are investigating and what has actually been established in people.

Here is what current research can tell us about CBN.

What Is CBN?

CBN stands for cannabinol.

It is a naturally occurring cannabinoid associated closely with the chemical changes that happen to Delta 9 THC as cannabis ages.

Unlike cannabinoids that are produced primarily through the plant's biosynthetic pathways, CBN is strongly associated with the degradation and oxidation of Delta 9 THC.

Researchers examining very old cannabis samples found that CBN was the dominant cannabinoid remaining in aged material, describing it as a major chemical degradation product of Delta 9 THC.

More recent laboratory research examining Delta 9 THC degradation and CBN formation has shown that temperature and other environmental conditions can influence these chemical changes.

So the simple idea that CBN is "made by exposing THC to light" is incomplete.

Aging, oxidation, heat, storage conditions, and other environmental factors can all be relevant to cannabinoid stability and the formation of CBN.

Does Old Cannabis Contain More CBN?

It can.

Because CBN is associated with Delta 9 THC degradation, aged cannabis may develop a different cannabinoid profile than fresher material.

An analysis of cannabis samples dating from approximately 1896 to 1905 found that much of the remaining cannabinoid content existed as CBN, although the researchers also identified other cannabinoids and degradation products.

That does not mean every older cannabis sample will contain the same CBN concentration.

Storage conditions, starting cannabinoid composition, light, temperature, oxygen exposure, and time can all influence what happens to a particular sample.

CBN vs. CBD vs. Delta 9 THC

CBN, CBD, and Delta 9 THC are different molecules with different chemical origins and pharmacology.

CannabinoidBasic DescriptionCommon Research ContextCBNCannabinoid strongly associated with oxidation and degradation of Delta 9 THCSleep research, receptor pharmacology, preclinical studiesCBDMajor non-intoxicating cannabinoid with a different biosynthetic pathwayBroad clinical and preclinical researchDelta 9 THCIntoxicating cannabinoid with substantial CB1 receptor activityIntoxication, cognition, appetite, pain, and other research areas

A 2025 review comparing the receptor pharmacology of major phytocannabinoids found substantial differences among CBN, CBD, Delta 9 THC, CBG, and CBC, including differences in their affinity for CB1 and CB2 cannabinoid receptors.

That matters because cannabinoids should not be treated as interchangeable simply because they come from the same plant.

How Does CBN Interact With the Endocannabinoid System?

The endocannabinoid system includes naturally produced signaling molecules, enzymes, and cannabinoid receptors.

Two of the most studied receptors are CB1 and CB2.

CB1 receptors are widely distributed throughout the central nervous system, while CB2 receptors are found in several tissues and are frequently studied in relation to immune signaling.

A 2025 systematic review and receptor-affinity analysis found that CBN has measurable affinity for both CB1 and CB2 receptors. Its receptor profile differs substantially from CBD and is also distinct from Delta 9 THC.

Researchers have additionally studied CBN at other molecular targets, including transient receptor potential channels.

For example, laboratory research examining multiple cannabinoids and TRP channels found that CBN interacted with TRPA1 in the experimental system used.

These findings help scientists investigate how CBN behaves at the molecular level.

They do not, by themselves, establish a particular health outcome from consuming a CBN product.

Does CBN Get You High?

The answer is not as simple as describing CBN as either fully intoxicating or completely nonpsychoactive.

Human research on isolated CBN is limited.

One frequently cited 1975 human experiment comparing CBN with Delta 9 THC involved only five male participants. In that study, 50 mg of CBN by itself did not produce the same reports of feeling drugged, drunk, dizzy, or drowsy that occurred after 25 mg of Delta 9 THC.

When researchers combined CBN with Delta 9 THC, however, some subjective responses changed.

The study is extremely small and nearly five decades old, so it should not be treated as the final word on CBN.

More recent receptor research confirms that CBN interacts with cannabinoid receptors, but receptor affinity does not automatically tell us exactly what a cannabinoid will feel like in humans.

The evidence therefore does not support simple claims such as:

• "CBN is one-quarter as intoxicating as THC."
• "CBN definitely gets you high."
• "CBN is completely nonpsychoactive."

A more accurate conclusion is that CBN's subjective effects in humans remain less well characterized than those of Delta 9 THC.

Why Is CBN Associated With Sleep?

CBN's reputation as a sleep cannabinoid developed long before researchers had strong controlled human evidence to support it.

In 2021, a review specifically asking whether clinical evidence supported sleep claims for CBN concluded that the available research at the time was too limited and outdated to substantiate the widespread marketing claims.

That situation has changed somewhat.

Several randomized controlled studies have since evaluated CBN and sleep.

The newer evidence is more informative, but it is also a good example of why CBN should not simply be called a proven sleep aid.

What Does the 20 mg CBN Sleep Study Show?

A double-blind, randomized, placebo-controlled study published in 2024 included 293 adults who described their sleep quality as poor or very poor.

Participants received one of several formulations for seven nights, including:

• placebo;
• 20 mg CBN;
• 20 mg CBN plus different amounts of CBD.

The primary outcome was overall sleep quality.

Compared with placebo, 20 mg CBN did not produce a statistically significant result on the study's primary sleep-quality outcome.

However, researchers did observe significant reductions in:

• the number of nighttime awakenings;
• overall reported sleep disturbance.

The study did not find significant differences for sleep-onset latency, wake after sleep onset, or daytime fatigue.

Adding CBD did not improve the CBN results.

That gives researchers useful information, but it is more nuanced than saying, "CBN makes you sleep better."

What Did the 2024 CBN Formulation Study Find?

Another randomized, double-blind, placebo-controlled study published in 2024 compared proprietary CBN formulations containing 25 mg, 50 mg, or 100 mg CBN with placebo and a melatonin group.

The study reported improvements in self-reported sleep quality among the CBN groups compared with placebo.

It did not find significant differences between the CBN groups and melatonin for the main sleep-quality comparison.

The trial also found no significant differences from placebo in its exploratory anxiety, pain, or general well-being measures, although the 100 mg group showed a larger decrease in reported stress.

This study adds another piece of evidence, but some context is important: it evaluated proprietary formulations, relied heavily on participant-reported outcomes, and does not by itself establish that every retail CBN product will produce the same results.

What Did the 2026 Insomnia Study Find?

One of the most informative recent studies specifically enrolled people with diagnosed insomnia.

In the 2026 randomized, double-blind, placebo-controlled crossover trial, 20 adults with insomnia received:

• 30 mg CBN;
• 300 mg CBN;
• placebo

on separate laboratory nights.

Unlike studies relying entirely on questionnaires, this experiment used overnight polysomnography, an objective measurement of sleep.

The primary outcome was wake after sleep onset, meaning how much time participants remained awake after initially falling asleep.

Neither 30 mg nor 300 mg CBN significantly improved that primary outcome compared with placebo.

However, the 300 mg condition produced changes in several secondary measures, including:

• shorter sleep-onset latency;
• improved subjective sleep quality;
• increased stage N2 sleep;
• lower EEG arousal indices.

Researchers reported numerous mild-to-moderate adverse events across the study conditions and concluded that larger, longer trials are needed.

This study is particularly useful because it demonstrates why a simple statement such as "CBN treats insomnia" would overstate the evidence.

Some measures changed. The primary outcome did not.

So, Does CBN Help With Sleep?

The best current answer is:

Human research now provides some evidence that CBN can affect certain sleep measures, but results vary by study, dose, outcome, and measurement method.

That is more encouraging than the evidence base available several years ago, but it still does not justify treating every CBN product as a clinically established sleep treatment.

The evidence includes:

• positive findings for some subjective sleep measures;
• reductions in nighttime awakenings in one trial;
• some positive secondary outcomes in people with diagnosed insomnia;
• primary outcomes that did not reach significance in other studies;
• relatively short study durations;
• limited objective sleep data;
• variation in dose and formulation.

So the scientifically responsible description is that CBN and sleep are an active area of human research, not that CBN is definitively "the sleep cannabinoid."

Does More CBN Mean Better Sleep?

Current research does not establish a simple rule that more CBN automatically produces better sleep.

The trials themselves illustrate the problem.

Researchers have evaluated amounts ranging from 20 mg to 300 mg, but the studies differ substantially in:

• participant populations;
• duration;
• formulations;
• outcome measures;
• study design.

The 2026 insomnia trial found some secondary changes with 300 mg while its primary objective sleep outcome remained nonsignificant.

That is not evidence for a consumer rule such as "higher CBN is better."

A milligram number tells you how much CBN a product reports. It does not guarantee a specific result.

Is CBN Equivalent to Valium?

No established evidence supports the claim that 5 mg of CBN equals 10 mg of Valium.

That comparison has circulated widely in cannabinoid marketing, but modern controlled human research does not establish a milligram-for-milligram equivalence between CBN and diazepam.

CBN and diazepam are different compounds with different pharmacology.

The newer randomized CBN sleep trials study CBN on its own terms rather than treating it as a substitute for a prescription benzodiazepine.

This is an important example of why cannabinoid claims should be traced back to actual research rather than repeated because they appear frequently online.

What Other CBN Research Is Being Conducted?

Sleep is not the only area researchers have investigated.

CBN has appeared in laboratory and animal research involving several biological systems.

The critical point is that preclinical research identifies questions worth studying. It does not establish that consumer CBN products treat diseases in people.

CBN and Bacteria

A 2008 laboratory study of cannabinoids and MRSA found that CBN and several other cannabinoids showed antibacterial activity against the bacterial strains tested.

More recently, researchers have continued investigating cannabinoids, including CBN, against MRSA biofilms.

These are laboratory findings.

They do not establish that taking CBN treats bacterial infections in humans.

CBN and Brain Research

Researchers are also investigating CBN in cellular and animal models involving brain aging and cellular stress.

A 2025 study of CBN in an accelerated-aging mouse model reported changes involving cognition, synaptic function, and mitochondrial health.

Because the experiment involved mice and laboratory models, those findings cannot establish that CBN prevents Alzheimer's disease, reverses human cognitive decline, or protects the human brain from aging.

They provide hypotheses for further research.

CBN and Inflammatory Pain Research

A 2026 experiment involving inflammatory pain in rats compared CBN, CBD, and THCV in an animal model and reported changes in some measures of pain sensitivity.

Again, this was a rat study.

It should not be converted into a retail claim that CBN gummies, tinctures, or other products provide established pain relief in humans.

CBN and Appetite Research

CBN has also been examined in animal feeding experiments.

A study of CBN and feeding behavior in rats found changes in food intake after CBN administration.

That does not establish CBN as an appetite treatment in people and should not be extrapolated to patients receiving chemotherapy or people with eating disorders.

CBN and Eye Research

CBN has been investigated in preclinical models related to the eye.

For example, a study using cell and animal models relevant to glaucoma research examined CBN in relation to retinal cells and intraocular pressure.

That research does not establish CBN as a treatment for glaucoma.

Why Preclinical Research and Human Evidence Are Different

This distinction matters throughout cannabinoid research.

Researchers commonly begin with:

• isolated receptors;
• cultured cells;
• laboratory chemistry;
• animal models.

These approaches help scientists understand mechanisms and decide whether human research may be worthwhile.

But a result in a test tube or mouse does not automatically tell us:

• whether the same thing happens in humans;
• what amount would be relevant;
• whether the effect is clinically meaningful;
• whether the result can be reproduced;
• whether the compound works in a retail product;
• what risks might emerge with regular use.

The responsible way to discuss CBN is therefore to identify what type of research produced the finding.

What CBN Research Does Not Currently Prove

Current evidence does not justify presenting retail CBN products as proven treatments for:

• insomnia;
• anxiety;
• chronic pain;
• arthritis;
• bacterial infections;
• Alzheimer's disease;
• ALS;
• glaucoma;
• epilepsy;
• appetite disorders;
• cancer.

Some of these subjects have appeared in laboratory or animal research.

That is different from established therapeutic effectiveness in humans.

CBN Products: What Forms Are Available?

CBN can appear in several types of cannabinoid products.

Depending on the manufacturer, these may include:

• Gummies
• Tinctures
• Capsules or softgels
• Oils
• Multi-cannabinoid blends
• Other edible formulations

CBN is also frequently paired with cannabinoids such as:

• CBD
• Delta 9 THC
• CBG

When several cannabinoids appear in one formula, the product should not be treated as though any observed effect can automatically be attributed to CBN alone.

That distinction also matters when interpreting research.

A study using isolated CBN tells us something different from a study involving CBN, CBD, and THC together.

CBN Alone vs. CBN Blends

A product containing only CBN and a product combining several cannabinoids are different formulations.

That sounds obvious, but it is especially important in cannabinoid research because combinations can make it difficult to determine which ingredient produced a particular result.

The 2024 randomized study of CBN with and without CBD is a useful example. Adding CBD at the tested amounts did not improve the sleep outcomes observed with 20 mg CBN alone.

Older human research also suggests that CBN may interact differently when administered alongside Delta 9 THC, although the evidence is extremely limited. The 1975 five-person study of CBN and Delta 9 THC observed differences between isolated CBN and cannabinoid combinations.

This is why multi-cannabinoid products should be evaluated according to their complete formulation.

How Much CBN Is in a Product?

CBN product labels typically report cannabinoid content in milligrams.

Pay attention to whether the number describes:

• CBN per piece;
• CBN per serving;
• total CBN in the package.

For example, a package containing 300 mg CBN across 30 gummies does not provide 300 mg in each gummy.

The label should make that distinction clear.

Also check whether the product contains CBN alone or divides its total cannabinoid content among CBN, CBD, Delta 9 THC, or other cannabinoids.

Why a CBN COA Matters

A Certificate of Analysis, or COA, provides laboratory-reported information about a tested sample.

Depending on the analysis performed, a cannabinoid panel may show:

• CBN
• CBD
• Delta 9 THC
• CBG
• Other cannabinoids included in the test

When reviewing a COA, look for information connecting the report with the product you are considering, such as:

• Product or sample name
• Batch or lot number
• Test date
• Cannabinoid results

Some reports also include additional testing.

Do not assume that "lab tested" means every possible analyte was tested. Read the laboratory document to see what the report actually covers.

What Should You Look for When Comparing CBN Products?

Rather than selecting a product based entirely on words such as "sleep," "nighttime," or "relaxation," compare the actual formulation.

Look at:

CBN amount: How much CBN is reported per piece or serving?

Other cannabinoids: Does the product also contain CBD, Delta 9 THC, CBG, or another cannabinoid?

Package count: How many pieces or servings are included?

Product format: Is it a gummy, tincture, capsule, or another formulation?

Ingredients: What else is included in the product?

Laboratory information: Is product- or batch-specific testing available?

Manufacturer directions: What information does the manufacturer provide about its formulation?

These characteristics are more concrete than assuming that all CBN products produce the same experience.

Can You Shop for CBN at Apotheca?

Apotheca carries a changing selection of products containing CBN, including individual cannabinoid and blended formulations.

Because product composition varies, use each product page to review the current:

• CBN amount
• Other cannabinoids
• Flavor
• Package size
• Product type
• Available laboratory information

Avoid assuming that two products containing CBN are interchangeable just because CBN appears on both labels.

Frequently Asked Questions About CBN

What does CBN stand for?

CBN stands for cannabinol, a cannabinoid strongly associated with the oxidation and degradation of Delta 9 THC.

Research on aged cannabis samples identified CBN as a major degradation product of Delta 9 THC.

Is CBN the same as CBD?

No.

CBN and CBD are separate cannabinoids with different chemical structures, origins, and receptor pharmacology.

A 2025 comparison of phytocannabinoid receptor activity found substantial pharmacological differences among CBN, CBD, Delta 9 THC, CBG, and CBC.

Is CBN the same as THC?

No.

CBN and Delta 9 THC are separate compounds.

CBN can form as Delta 9 THC undergoes degradation and oxidation, but the two cannabinoids have different pharmacological and subjective profiles.

Does CBN make you sleepy?

CBN is strongly marketed for sleep, and recent controlled human research has reported changes in some sleep measures.

However, the studies have produced mixed results.

A 2024 randomized trial of 20 mg CBN found fewer nighttime awakenings and less overall sleep disturbance but did not meet statistical significance on its primary sleep-quality outcome.

A 2026 laboratory study in adults with diagnosed insomnia found no significant improvement in its primary objective measure of wake after sleep onset, although the higher tested amount changed several secondary measures.

So CBN's relationship with sleep remains an active area of research rather than a settled guarantee.

Is CBN a sedative?

Calling CBN a proven sedative is too broad based on current human evidence.

Older research was limited, and modern sleep trials have produced a mixture of positive and nonsignificant findings.

The 2021 review that examined the historical sleep evidence for CBN found that the evidence available at that time did not substantiate common sleep-marketing claims. Newer studies have added useful information but have not made the evidence completely uniform.

Is 5 mg CBN equivalent to 10 mg Valium?

No reliable human evidence establishes that equivalence.

CBN and diazepam are pharmacologically different compounds, and modern controlled CBN research does not support presenting one as a milligram-for-milligram substitute for the other.

Does CBN get you high?

Human evidence is limited.

In a very small 1975 human study, 50 mg isolated CBN did not produce the same reports of intoxication seen after Delta 9 THC.

Because the study involved only five participants, it should be interpreted cautiously.

CBN should not simply be described as either "THC without the high" or a guaranteed intoxicant.

Does CBN treat pain?

Laboratory and animal research has investigated CBN in pain-related models.

A 2026 rat study involving inflammatory pain reported changes in some pain-sensitivity measures after CBN administration.

Animal evidence does not establish that commercial CBN products provide pain relief in humans.

Is CBN antibacterial?

CBN has demonstrated antibacterial activity in laboratory experiments.

A 2008 in-vitro study found activity against several MRSA strains.

That does not establish oral or topical CBN products as treatments for bacterial infections.

Is CBN good for Alzheimer's disease?

Current evidence does not establish CBN as an Alzheimer's treatment or prevention strategy.

A 2025 mouse study of age-related cognitive decline produced findings relevant to ongoing brain-aging research, but mouse experiments cannot establish effectiveness in people with Alzheimer's disease.

Is more CBN better?

Current research does not establish a rule that larger CBN amounts automatically produce better results.

Human sleep studies have used substantially different amounts and produced different outcomes.

The CBN number on a product is best treated as a formulation specification, not a guarantee of effectiveness.

The Bottom Line on CBN

CBN is a scientifically interesting cannabinoid with a research history that now spans decades.

We know that:

• CBN is closely associated with the degradation and oxidation of Delta 9 THC.
• CBN has a distinct receptor and pharmacological profile.
• Human research on CBN is still much smaller than the research base for CBD or Delta 9 THC.
• Several modern randomized trials have investigated CBN and sleep.
• Those sleep trials have produced some positive findings, but the results are not uniformly positive across primary and secondary outcomes.
• Laboratory and animal studies have investigated CBN in areas including bacteria, brain aging, inflammation, pain, appetite, and eye biology.
• Those preclinical findings should not be presented as proven medical benefits in humans.

The most significant change in CBN research over the last several years is that we are beginning to get controlled human data rather than relying almost entirely on anecdote and older laboratory research.

That makes the science more useful, but it also makes overly simple claims easier to identify.

CBN should not be described as a guaranteed sleep aid, a natural substitute for prescription medication, or a proven treatment for pain, neurological disease, glaucoma, epilepsy, infections, or other medical conditions.

Instead, treat CBN as what the evidence currently supports: a distinct cannabinoid with emerging human research, particularly around sleep, and a much larger body of preclinical research that still requires further study.

If you are comparing products, you can browse CBN products at Apotheca and review each product's current cannabinoid amounts, formulation, package information, and available laboratory documentation.